smartpathdigital.com
News | Smartpath Digital
http://www.smartpathdigital.com/news
Skip to main content. Fresh from the News Feed. Riffyn Secures $1.8 Million Seed Financing to Advance Reproducible Research. Mon, 17/11/2014 - 13:53. Riffyn Secures $1.8 Million Seed Financing to Advance Reproducible Research with O’Reilly AlphaTech Ventures Leading the Financing Round. J CRAIG VENTER TO KEYNOTE at SYNBIOBETA SF 2014. Tue, 04/11/2014 - 15:28. Legendary bio-pioneer J. Craig Venter to keynote at Synbiobeta in San Francisco 2014. Wed, 15/10/2014 - 10:54. Mon, 13/10/2014 - 11:30. Domainex Re...
pharmahub.leeds.ac.uk
Who we work with: Pharma hub, University of Leeds
http://pharmahub.leeds.ac.uk/home/who-we-work-with.html
Pharmaceuticals and Biotechnology Innovations at Astbury. You are here: Unversity of Leeds. Who we work with. Who we work with. Targeted Skin Therapeutics - Building Partnerships. Partners in developing better treatments. Who we work with. We work with a wide range of companies and partners in the pharmaceutical industry - including:. Lorien Engineering Solutions Limited.
discoverychemistry-congress1.com
2016 Sponsors – Oxford Global Marketing – 5th Annual Discovery Chemistry & Drug Design Congress, 12 -13 June 2017, Berlin, Germany
http://www.discoverychemistry-congress1.com/solution-providers/sponsors
Oxford Global Marketing – 5th Annual Discovery Chemistry and Drug Design Congress, 12 -13 June 2017, Berlin, Germany. Admescope is a contract research organisation (CRO) providing the pharmaceutical, biotechnology and veterinary industry with tailor made services to drug discovery in the area of ADME-Tox. The service offering is widely spread over the whole ADME-Tox area, from highly tailored and optimised studies to High Throughput Screening (HTS). Admescope’s unique top-notch expertise lies in. These d...
pharma.biotech.leeds.ac.uk
Who we work with: Pharma hub, University of Leeds
http://www.pharma.biotech.leeds.ac.uk/home/who-we-work-with.html
Pharmaceuticals and Biotechnology Innovations at Astbury. You are here: Unversity of Leeds. Who we work with. Who we work with. ABSL Open Innovation event 1st March 2017. Partners in developing better treatments. Who we work with. We work with a wide range of companies and partners in the pharmaceutical industry - including:. Lorien Engineering Solutions Limited.
drugdiscoverychemistry.com
Fragment-Based Drug Discovery Conference
http://www.drugdiscoverychemistry.com/Fragment-Based-Drug-Discovery
From Hits to Leads and Lessons Learned. April 25-26, 2017 Sheraton San Diego Hotel and Marina. Scientific Advisor: Daniel A.Erlanson, Ph.D., Co-Founder,CarmotTherapeutics, Inc. Day 1 Day 2. Tuesday, April 25. FRAGMENTS TO LEADS AND CANDIDATES. Daniel A. Erlanson, Ph.D., Co-Founder, Carmot Therapeutics, Inc. Late-Breaking Presentation: Expanding the Ligandable Proteome: Ligand and Target Discovery by Fragment-Based Screening in Human Cells. Small molecule inhibitors of interleukin-1 receptor-associated ki...
sciad.com
Clients | SCIAD
http://www.sciad.com/clients
The Science of Communications. Brand Strategy and Design. Who We Work With. Sciad Clients in Science, Tech and Health. Sciad works with clients offering cost-effective, direct, cutting edge online marketing techniques. Design of corporate identity, development of website, PR distribution and media liaison. Design and development of Domainex's website, digital marketing, marketing literature, PR distribution and media liaison. Sciad developed the new website for Medherant, the name of the TEPI Patch.
sciadnewswire.com
Domainex Launches New BioassayBuilder Service to Strengthen its Drug Discovery Platform | Sciad Newswire
http://www.sciadnewswire.com/news/204/domainex-launches-new-bioassaybuilder-service-strengthen-its-drug-discovery-platform
Science and Healthcare Distribution. Domainex Launches New BioassayBuilder Service to Strengthen its Drug Discovery Platform. Wed, 01/07/2015 - 08:00. Cambridge, UK, 1st July 2015 / Sciad Newswire. In addition, BioassayBuilder can be integrated with the biophysical assays offered by our strategic partner ZoBio, including their proprietary. Target Immobilized NMR Screening. Founded in 2002, Domainex is based in Cambridge, UK. It is one of the fastest growing UK biotechnology companies and a leading pr...
takedaventures.com
Takeda Ventures, Inc. > TVI Portfolio
http://www.takedaventures.com/portfolio
Skip to main content. ArmaGen, Inc (CA, USA). Has developed a receptor transcytosis Trojan Horse technology platform enabling non-invasive delivery of biotherapeutics across the blood-brain barrier. The company is initially focusing on treatment of lysosomal storage diseases, where CNS involvement cannot be addressed by current standards of care. CellCentric, Ltd. (Cambridge, UK). Domainex, Ltd (Cambridge, UK). Encycle Therapeutics, Inc. (ON, Canada). Is pioneering the development of nacellins, small cyc...
zobio.com
ZOBIO AND DOMAINEX JOIN FORCES TO DELIVER CRUCIAL DRUG TARGET INFORMATION TO SUPPORT FORMA THERAPEUTICS’ DRUG DISCOVERY PROGRAMS | ZoBio - Drug Discovery Technology
http://www.zobio.com/zobio-and-domainex-join-forces-to-deliver-crucial-drug-target-information-to-support-forma-therapeutics-drug-discovery-programs
Tools for fragment based drug discovery. VALIDATION & CHARACTERIZATION. HIT TO LEAD DEVELOPMENT. ZOBIO AND DOMAINEX JOIN FORCES TO DELIVER CRUCIAL DRUG TARGET INFORMATION TO SUPPORT FORMA THERAPEUTICS’ DRUG DISCOVERY PROGRAMS. ZOBIO AND DOMAINEX JOIN FORCES TO DELIVER CRUCIAL DRUG TARGET INFORMATION TO SUPPORT FORMA THERAPEUTICS’ DRUG DISCOVERY PROGRAMS. 8 December 2014, Leiden, NL. Today ZoBio and Domainex Ltd. Cambridge, UK) announce a collaboration with FORMA Therapeutics. Gregg Siegal, CEO of ZoBio s...
SOCIAL ENGAGEMENT